0001209191-19-028847.txt : 20190510 0001209191-19-028847.hdr.sgml : 20190510 20190510160150 ACCESSION NUMBER: 0001209191-19-028847 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190510 DATE AS OF CHANGE: 20190510 EFFECTIVENESS DATE: 20190510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Novus Therapeutics, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-339368 FILM NUMBER: 19814779 BUSINESS ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 D 1 primary_doc.xml X0708 D LIVE 0001404281 Novus Therapeutics, Inc. 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 (949) 238-8090 DELAWARE Tokai Pharmaceuticals, Inc. Tokai Pharmaceuticals Inc Corporation true Gregory Flesher 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Executive Officer Director Erez Chimovits 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Director Cheryl Cohen 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Director Keith Katkin 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Director John McBride 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Director Gary Lyons 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Director Catherine Turkel 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Executive Officer Jon Kuwahara 19900 MacArthur Boulevard Suite 550 Irvine CA CALIFORNIA 92612 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2019-05-02 false true true false 0 H.C. Wainwright and Co., LLC None H.C. Wainwright and Co., LLC 375 430 Park Avenue New York NY NEW YORK 10022 All States 28455174 862278 27592896 Includes proceeds from the sale of 3,449,112 Series A warrants and 3,449,112 Series B Warrants at $0.125 per warrant and the 6,898,224 shares of common stock issuable upon the exercise of such warrants at an exercise price of $4 per share. false 10 60359 0 H.C. Wainwright & Co., LLC received the above sales commission in connection with the sale of the Series A warrants and Series B warrants. 0 Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering. false Novus Therapeutics, Inc. /s/ Gregory J. Flesher Gregory J. Flesher Chief Executive Officer 2019-05-10